The group's principal activity is to develop innovative biotechnology products designed to improve the safety of the blood supply. The group has designed the proprietary inactine(tm) system to inactivate a wide range of viruses, bacteria, parasites and lymphocytes from red blood cells. The inactine(tm) system has also demonstrated the ability to remove prion proteins that may cause mad cow disease in cows and the human form of the disease, variant creutzfeldt-jakob disease (vcjd). The technology works by binding to the rna or dna of the pathogen. Once bound, the compound forms an irreversible bond to the pathogenic nucleic acid, preventing replication and thereby killing the pathogens.
Executive Information
Name
Title
Email
Jeremy Hayward-Surry
Chmn.
N/A
Graham Allaway
COO
N/A
Scott McCallister
Chief Medical Officer
N/A
David Martin
Sr. VP - Drug Development
N/A
Frederick Schmid
Sr. VP - Commercial Operations, Business Development
